PIQ

2.75%

88.5¢ proteomics international laboratories ltd

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-34

First 34 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

17/07/21

14:03

Post #: 54572435
Share

Originally posted by Torpy: ↑

Cheers Owl, glad to be in good company
A relative newcomer here and still getting fully up to speed on the science and business case.
Good find on the PBS history with canagliflozin. To my mind this is all about reimbursement and insurance. If you can avoid greater costs down the road, then subsidising early stage diagnositc and pre-emptive/preventative treatment is a straight forward equation.
The Stage 2 results seem good and the announcement title almost downplays the significance. Yes Stage 2 showed the "drug improved PromarkerD scores" but when you combine that with the Stage 1 outcome (that the scores correctly predict risk of severe disease) the implication is that the "drug improves risk of severe disease". This seems to be leading to demonstrating "disease modification" for the drug which would presumably be a huge thing for both Janssen, and PromarkerD.
I liken this a little to Paradigm who are in the process of demonstrating disease modification of their drug for OsteoArthritis. The consequence of untreated knee OA is ultimately a total knee replacement at about $30,000, so for insurers/reimbursers a treatment plan that avoids this has huge value. PAR are going to great lengths to prove the disease modifying effects (which interestingly includes a biomarker study) to make this business case compelling.
I'm new here on PIQ and still learning more about the DKD space, but this seems to be the general strategy?

Expand

I think you have it! I knew you would.

PIQ Price at posting: $1.08 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GRX

GreenX picks up prospective copper project in Germany

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

There are more pages in this discussion • 20 more messages in this thread...

First 34 Last

Add PIQ (ASX) to my watchlist

(20min delay)
Last 88.5¢		Change -0.025(2.75%)		Mkt cap ! $115.9M

Open	High	Low	Value	Volume
90.0¢	91.0¢	88.0¢	$87.82K	98.58K

Buyers (Bids)

No.	Vol.	Price($)
3	47698	88.5¢

Sellers (Offers)

Price($)	Vol.	No.
89.5¢	1666	1

View Market Depth

No.	Vol.	Price($)
3	47698	0.885
1	29896	0.880
3	15430	0.870
4	16400	0.860
6	12542	0.850

Price($)	Vol.	No.
0.895	1666	1
0.900	30000	2
0.910	27142	2
0.920	1177	1
0.940	15328	2

Last trade - 14.49pm 02/08/2024 (20 minute delay)

PIQ (ASX) Chart

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-34

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Study shows diabetes drug improves PromarkerD risk scores, page-34

Top Stories

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News